BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30214690)

  • 1. Identification of a novel gene fusion in ALT positive osteosarcoma.
    Mason-Osann E; Dai A; Floro J; Lock YJ; Reiss M; Gali H; Matschulat A; Labadorf A; Flynn RL
    Oncotarget; 2018 Aug; 9(67):32868-32880. PubMed ID: 30214690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
    Clatterbuck Soper SF; Meltzer PS
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells.
    Yost KE; Clatterbuck Soper SF; Walker RL; Pineda MA; Zhu YJ; Ester CD; Showman S; Roschke AV; Waterfall JJ; Meltzer PS
    Sci Rep; 2019 Mar; 9(1):4544. PubMed ID: 30872698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization.
    Li F; Deng Z; Zhang L; Wu C; Jin Y; Hwang I; Vladimirova O; Xu L; Yang L; Lu B; Dheekollu J; Li JY; Feng H; Hu J; Vakoc CR; Ying H; Paik J; Lieberman PM; Zheng H
    EMBO J; 2019 Oct; 38(19):e96659. PubMed ID: 31454099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres.
    Lewis PW; Elsaesser SJ; Noh KM; Stadler SC; Allis CD
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14075-80. PubMed ID: 20651253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
    Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
    Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of ATRX or DAXX mutated neuroblastoma.
    Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
    J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
    VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
    Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
    Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
    Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compromised Telomeric Heterochromatin Promotes ALTernative Lengthening of Telomeres.
    Voon HPJ; Collas P; Wong LH
    Trends Cancer; 2016 Mar; 2(3):114-116. PubMed ID: 28741530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
    Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
    Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
    Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
    PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
    Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATRX Plays a Key Role in Maintaining Silencing at Interstitial Heterochromatic Loci and Imprinted Genes.
    Voon HP; Hughes JR; Rode C; De La Rosa-Velázquez IA; Jenuwein T; Feil R; Higgs DR; Gibbons RJ
    Cell Rep; 2015 Apr; 11(3):405-18. PubMed ID: 25865896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity.
    Lovejoy CA; Takai K; Huh MS; Picketts DJ; de Lange T
    PLoS Biol; 2020 Jan; 18(1):e3000594. PubMed ID: 31895940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.